Plain-English translation of NCT03578185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Researchers are studying tissue samples from lung cancer patients who have been treated with immunotherapy to identify genetic markers—like fingerprints in your DNA—that predict whether the medication will work well for you. By understanding these patterns, doctors hope to better match patients with the right immunotherapy treatments in the future.
Immunotherapy helps some lung cancer patients but not others, and doctors don't yet have reliable ways to predict who will respond. This study aims to discover genetic clues that could help doctors choose the best treatment for each patient upfront.
You likely qualify if…
You likely don't qualify if…
If you have leftover tissue samples from previous medical procedures or clinical trials, researchers may ask permission to use those samples for genetic analysis. You would sign a master agreement allowing your samples to be studied, and researchers would review your medical records—including your cancer diagnosis date, treatments you received, and how you responded to them. There are no additional visits or procedures required beyond donating existing tissue samples.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
South Korea
Sponsor
Samsung Medical Center
Enrollment target
~2,000 participants
Started
April 2018
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Se-hoon Lee, MD
Samsung Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.